$AORT
ARTIVION, INC. Stock $aort

$aort Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000078419922000076 Filed on February 22, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$79.39M	$298.8M	$67.90M
YoY Change	16.93%	18.01%	-2.58%
Cost Of Revenue	$28.02M	$101.3M	$23.31M
YoY Change	20.23%	18.58%
Gross Profit	$51.37M	$197.5M	$44.59M
YoY Change	15.21%	17.72%	-4.21%
Gross Profit Margin	64.71%	66.09%	65.68%
Selling, General & Admin	$32.14M	$169.8M	$26.97M
YoY Change	19.17%	20.29%
% of Gross Profit	62.56%	85.96%	60.48%
Research & Development	$9.460M	$35.55M
YoY Change		46.84%
% of Gross Profit	18.41%	18.0%
Depreciation & Amortization	$5.969M	$23.98M	$5.894M
YoY Change	1.27%	15.76%
% of Gross Profit	11.62%	12.14%	13.22%
Operating Expenses	$45.81M	$205.3M	$37.88M
YoY Change	20.95%	24.18%
Operating Profit	$5.561M	$8.117M	$6.714M
YoY Change	-17.17%	232.53%
Interest Expense	-$3.873M	$16.90M	-$4.682M
YoY Change	-17.28%	1.2%
% of Operating Profit	-69.65%	208.21%	-69.73%
Other Income/Expense, Net	-$2.875M	-$6.136M	$2.676M
YoY Change	-207.44%	95.79%
Pretax Income	-$16.09M	-$14.83M	-$92.00K
YoY Change	17385.87%	-13.67%
Income Tax	$4.013M	$7.000K	$3.366M
% Of Pretax Income
Net Earnings	-$20.10M	-$14.83M	-$3.458M
YoY Change	481.26%	-11.08%	407.78%
Net Earnings / Revenue	-25.32%	-4.96%	-5.09%
Basic Earnings Per Share		-$0.38
Diluted Earnings Per Share	-$513.3K	-$0.38	-$89.54K
COMMON SHARES
Basic Shares Outstanding	39.33M	38.98M	38.86M
Diluted Shares Outstanding		38.98M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$55.01M	$55.01M	$61.41M
YoY Change	-10.42%	-10.42%
Cash & Equivalents	$55.01M	$55.01M	$61.41M
Short-Term Investments
Other Short-Term Assets	$57.61M	$57.61M	$51.39M
YoY Change	12.11%	12.11%
Inventory	$76.97M	$76.97M	$73.04M
Prepaid Expenses
Receivables	$53.02M	$53.02M	$45.96M
Other Receivables	$5.086M	$5.086M	$2.788M
Total Short-Term Assets	$247.7M	$247.7M	$234.6M
YoY Change	5.59%	5.59%	25.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$37.52M	$83.24M	$33.08M
YoY Change	13.44%	61.16%	2.88%
Goodwill	$250.0M		$260.1M
YoY Change	-3.87%		39.3%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.267M	$10.62M	$14.60M
YoY Change	-43.39%	-33.8%	2.78%
Total Long-Term Assets	$545.4M	$545.4M	$554.8M
YoY Change	-1.71%	-1.71%	32.65%
TOTAL ASSETS
Total Short-Term Assets	$247.7M	$247.7M	$234.6M
Total Long-Term Assets	$545.4M	$545.4M	$554.8M
Total Assets	$793.1M	$793.1M	$789.4M
YoY Change	0.46%	0.46%	30.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.40M	$10.40M	$9.623M
YoY Change	8.02%	8.02%	-1.77%
Accrued Expenses	$7.687M	$27.69M	$7.472M
YoY Change	2.88%	2.37%	10.98%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.630M	$2.158M	$1.195M
YoY Change	36.4%	19.29%	2.66%
Total Short-Term Liabilities	$44.95M	$44.95M	$60.47M
YoY Change	-25.66%	-25.66%	33.79%
LONG-TERM LIABILITIES
Long-Term Debt	$307.5M	$311.9M	$290.5M
YoY Change	5.86%	5.44%	35.37%
Other Long-Term Liabilities	$6.484M	$106.7M	$6.690M
YoY Change	-3.08%	53.0%	1.66%
Total Long-Term Liabilities	$314.0M	$418.6M	$297.2M
YoY Change	5.66%	14.52%	34.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.95M	$44.95M	$60.47M
Total Long-Term Liabilities	$314.0M	$418.6M	$297.2M
Total Liabilities	$492.3M	$492.3M	$460.7M
YoY Change	6.87%	6.87%	43.98%
SHAREHOLDERS EQUITY
Retained Earnings	$1.975M		$20.02M
YoY Change	-90.14%		-45.45%
Common Stock	$323.3M		$316.6M
YoY Change	2.11%		16.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$300.7M	$300.7M	$328.7M
YoY Change
Total Liabilities & Shareholders Equity	$793.1M	$793.1M	$789.4M
YoY Change	0.46%	0.46%	30.34%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$20.10M	-$14.83M	-$3.458M
YoY Change	481.26%	-11.08%	407.78%
Depreciation, Depletion And Amortization	$5.969M	$23.98M	$5.894M
YoY Change	1.27%	15.76%
Cash From Operating Activities	$716.0K	-$2.585M	$5.450M
YoY Change	-86.86%	-120.9%
INVESTING ACTIVITIES
Capital Expenditures	-$2.567M	$13.09M	-$2.157M
YoY Change	19.01%	78.64%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	-$245.0K	$249.0K	-$189.0K
YoY Change	29.63%	-85.19%
Cash From Investing Activities	-$2.812M	$5.660M	-$2.346M
YoY Change	19.86%	-107.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$3.756M
YoY Change		54.44%
Debt Paid & Issued, Net		$2.786M
YoY Change
Cash From Financing Activities	-8.801M	-12.22M	-1.682M
YoY Change	423.25%	-113.06%
NET CHANGE
Cash From Operating Activities	716.0K	-2.585M	5.450M
Cash From Investing Activities	-2.812M	5.660M	-2.346M
Cash From Financing Activities	-8.801M	-12.22M	-1.682M
Net Change In Cash	-10.90M	-6.948M	1.422M
YoY Change	-866.32%	-125.12%
FREE CASH FLOW
Cash From Operating Activities	$716.0K	-$2.585M	$5.450M
Capital Expenditures	-$2.567M	$13.09M	-$2.157M
Free Cash Flow	$3.283M	-$15.68M	$7.607M
YoY Change	-56.84%	-410.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	aort	Tax Credit Other Expiration Date TaxCreditOtherExpirationDate	2027-12-31
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000784199
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	us-gaap	Tax Credit Carryforward Expiration Date TaxCreditCarryforwardExpirationDate	2030-12-31
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	1-13165
CY2021	dei	Entity Registrant Name EntityRegistrantName	ARTIVION, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-2417093
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	1655 Roberts Boulevard N.W.
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Kennesaw
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30144
CY2021	dei	City Area Code CityAreaCode	770
CY2021	dei	Local Phone Number LocalPhoneNumber	419-3355
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $.01 par value
CY2021	dei	Trading Symbol TradingSymbol	AORT
CY2021	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55010000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	247697000
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1069799941
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40115521
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61412000
CY2020Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	546000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53019000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45964000
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	5086000
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2788000
CY2021Q4	us-gaap	Inventory Net InventoryNet	76971000
CY2020Q4	us-gaap	Inventory Net InventoryNet	73038000
CY2021Q4	aort	Deferred Preservation Costs DeferredPreservationCosts	42863000
CY2020Q4	aort	Deferred Preservation Costs DeferredPreservationCosts	36546000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14748000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14295000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	234589000
CY2021Q4	us-gaap	Goodwill Goodwill	250000000
CY2020Q4	us-gaap	Goodwill Goodwill	260061000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45714000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18571000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37521000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33077000
CY2021Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	34502000
CY2020Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	40966000
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2357000
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1446000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8267000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14603000
CY2021Q4	us-gaap	Assets Assets	793052000
CY2020Q4	us-gaap	Assets Assets	789404000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10395000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9623000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7687000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5763000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	60468000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	307493000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	290468000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	49400000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	43500000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44869000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14034000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7472000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13163000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10192000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	3634000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2808000
CY2021Q4	aort	Accrued Procurement Fees AccruedProcurementFees	3689000
CY2020Q4	aort	Accrued Procurement Fees AccruedProcurementFees	3619000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	528000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	614000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3149000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1630000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1195000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	16430000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1078000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2752000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44953000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4374000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	5300000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	28799000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	34713000
CY2021Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	5952000
CY2020Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	5518000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6484000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6690000
CY2021Q4	us-gaap	Liabilities Liabilities	492324000
CY2020Q4	us-gaap	Liabilities Liabilities	460691000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41397000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	101322000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	85443000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40394000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	414000
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	14648000
CY2020Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	14648000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	300728000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	328713000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	793052000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	789404000
CY2021	us-gaap	Revenues Revenues	298836000
CY2020	us-gaap	Revenues Revenues	253227000
CY2019	us-gaap	Revenues Revenues	276222000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	404000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	322874000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	316192000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1975000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	20022000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9887000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6743000
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1487000
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1487000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	93209000
CY2021	us-gaap	Gross Profit GrossProfit	197514000
CY2020	us-gaap	Gross Profit GrossProfit	167784000
CY2019	us-gaap	Gross Profit GrossProfit	183013000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	169774000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	141136000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	143011000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35546000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24207000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22960000
CY2021	us-gaap	Operating Expenses OperatingExpenses	205320000
CY2020	us-gaap	Operating Expenses OperatingExpenses	165343000
CY2019	us-gaap	Operating Expenses OperatingExpenses	165971000
CY2021	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	15923000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	8117000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	2441000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	17042000
CY2021	aort	Interest Expense Including Reversal Of Interest InterestExpenseIncludingReversalOfInterest	16887000
CY2020	aort	Interest Expense Including Reversal Of Interest InterestExpenseIncludingReversalOfInterest	16698000
CY2019	aort	Interest Expense Including Reversal Of Interest InterestExpenseIncludingReversalOfInterest	14886000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	79000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	217000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	738000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6136000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3134000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1250000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14827000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17174000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1644000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-492000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-76000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14834000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16682000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	1720000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38983000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37861000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37118000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38983000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37861000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37860000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14834000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16682000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	1720000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-16630000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	15332000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2517000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31464000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1350000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-797000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14834000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16682000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	1720000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23977000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20712000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18317000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10711000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	6912000
CY2020	aort	Noncash Lease Expense NoncashLeaseExpense	7145000
CY2019	aort	Noncash Lease Expense NoncashLeaseExpense	5009000
CY2021	aort	Write Down Of Deferred Preservation Costs And Inventories WriteDownOfDeferredPreservationCostsAndInventories	5377000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	8799000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	8870000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4523000
CY2021	aort	Noncash Lease Expense NoncashLeaseExpense	7521000
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	11560000
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-9938000
CY2020	aort	Write Down Of Deferred Preservation Costs And Inventories WriteDownOfDeferredPreservationCostsAndInventories	3443000
CY2019	aort	Write Down Of Deferred Preservation Costs And Inventories WriteDownOfDeferredPreservationCostsAndInventories	1488000
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	4944000
CY2021	aort	Noncash Interest Expense NoncashInterestExpense	2005000
CY2020	aort	Noncash Interest Expense NoncashInterestExpense	3656000
CY2019	aort	Noncash Interest Expense NoncashInterestExpense	1631000
CY2021	aort	Change In Fair Value Of Long Term Loan ChangeInFairValueOfLongTermLoan	409000
CY2020	aort	Change In Fair Value Of Long Term Loan ChangeInFairValueOfLongTermLoan	4949000
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	4470000
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-4283000
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	2305000
CY2021	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	15923000
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	2060000
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense	124000
CY2019	us-gaap	Other Noncash Expense OtherNoncashExpense	551000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1404000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2720000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6177000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1893000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-9157000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	251000
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	5332000
CY2021	aort	Increase Decrease In Deferred Preservation Costs And Inventories IncreaseDecreaseInDeferredPreservationCostsAndInventories	18375000
CY2020	aort	Increase Decrease In Deferred Preservation Costs And Inventories IncreaseDecreaseInDeferredPreservationCostsAndInventories	24757000
CY2019	aort	Increase Decrease In Deferred Preservation Costs And Inventories IncreaseDecreaseInDeferredPreservationCostsAndInventories	8125000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2585000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12369000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	15827000
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	19000000
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	59119000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5000000
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15000000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13091000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7328000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8072000
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	249000
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1681000
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	871000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5660000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73128000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23943000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3756000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2432000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1493000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2200000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5185000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4758000
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	100000000
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	30000000
CY2020	aort	Proceeds From Financing Insurance Premiums ProceedsFromFinancingInsurancePremiums	2815000
CY2020	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	30000000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1914000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1995000
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2743000
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2219000
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	3647000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3085000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5346000
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2780000
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	8200000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-561000
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-651000
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-728000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-12223000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	93608000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1667000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6948000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27664000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7942000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61958000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34294000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42236000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55010000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61958000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34294000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	275067000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	1720000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2517000
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	9411000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3295000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1463000
CY2019	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	2743000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	285696000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16682000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	15332000
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	20000000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	16426000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7504000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	871000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1561000
CY2020	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	1995000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	328713000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14834000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-16630000
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10000000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11277000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2146000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1609000
CY2021	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	1914000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	300728000
CY2021	us-gaap	Basis Of Accounting BasisOfAccounting	1. Basis of Presentation and Summary of Significant Accounting Policies Nature of Business Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stents and stent grafts, surgical sealants, On-X® mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stents and stent grafts include JOTEC® stent grafts and surgical products (collectively, “JOTEC Products”), the Ascyrus Medical Dissection Stent (“AMDS”) hybrid prosthesis, and the NEXUS® endovascular stent graft system (“NEXUS”). Surgical sealants include BioGlue® Surgical Adhesive (“BioGlue”) products. In addition to these four major product families, we sell or distribute PhotoFix® bovine surgical patches, CardioGenesis® cardiac laser therapy, Therion® chorioamniotic allografts (previously marketed as NeoPatch®), and PerClot® hemostatic powder (prior to the sale to a subsidiary of Baxter International, Inc (“Baxter”)). Basis of Presentation and Principles of Consolidation We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The accompanying consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain prior-year amounts have been reclassified to conform to the current year presentation. Foreign Currencies Our revenues and expenses transacted in foreign currencies are remeasured as they occur at exchange rates in effect at the time of each transaction. Realized and unrealized gains and losses on foreign currency transactions are recorded as a component of Other expense, net on our Consolidated Statements of Operations and Comprehensive Loss. Realized and unrealized gains and losses were a loss of $5.5 million, a gain of $1.8 million, and a loss of $1.2 million for the years ended December 31, 2021, 2020, and 2019, respectively. Our assets and liabilities denominated in foreign currencies are recognized at the exchange rate in effect at the time of each transaction. At period end, the assets and liabilities are translated at the exchange rate in effect as of the balance sheet date and are recorded as a separate component of accumulated other comprehensive loss in the shareholders' equity section of our Consolidated Balance Sheets. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with US GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Estimates and assumptions are used when accounting for allowance for doubtful accounts, inventory, deferred preservation costs, acquired assets or businesses, intangible assets, deferred income taxes, commitments and contingencies (including product and tissue processing liability claims, claims incurred but not reported, and amounts recoverable from insurance companies), stock based compensation, certain accrued liabilities (including accrued procurement fees, income taxes, and financial instruments), and other items as appropriate.‎ Revenue Recognition Contracts with Customers We routinely enter into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and, in most cases, prices for the products and services that we offer. These agreements, however, do not obligate us to provide goods or services to the customer, and there is no consideration promised to us at the onset of these arrangements. For customers without separate agreements, we have a standard list price established by geography and by currency for all products and services, and our invoices contain standard terms and conditions that are applicable to those customers where a separate agreement is not controlling. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time we have an unconditional right to receive payment. Our prices are fixed and are not affected by contingent events that could impact the transaction price. We do not offer price concessions and do not accept payment that is less than the price stated when we accept the purchase order, except in rare credit related circumstances. We do not have any material performance obligations where we are acting as an agent for another entity. Revenues for products, including: aortic stents and stent grafts, surgical sealants, On-X products, and other medical devices, are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenues from consignment are recognized when the medical device is implanted. We recognize revenues for preservation services when tissue is shipped to the customer. Warranty Our general product warranties do not extend beyond an assurance that the products or services delivered will be consistent with stated specifications and do not include separate performance obligations. Warranties included with our CardioGenesis cardiac laser products provide for annual maintenance services, which are priced separately and are recognized as revenues at the stand-alone price over the service period, whether invoiced separately or recognized based on our allocation of the transaction price. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product or service obligation to the customer. This is consistent with the time in which the customer obtains control of the product or service. Performance obligations are also generally settled quickly after the purchase order acceptance, other than as identified for E-xtra Design Engineering products, therefore, the value of unsatisfied performance obligations at the end of any reporting period is immaterial. For performance obligations provided through our E-xtra Design Engineering product line, we determine the value of our enforceable right to payment based on the time required and costs incurred for design services and manufacture of the in-process device in relation to the total inputs required to complete the device. We consider variable consideration in establishing the transaction price. Forms of variable consideration potentially applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products and services in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Commissions and Contract Costs Sales commissions are earned upon completion of each performance obligation, and therefore, are expensed when incurred. These costs are included in General, administrative, and marketing expenses in the Consolidated Statements of Operations and Comprehensive Loss. We generally do not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement. Practical Expedients Our payment terms for sales direct to customers are substantially less than the one-year collection period that falls within the practical expedient in the determination of whether a significant financing component exists. Shipping and Handling Charges Fees charged to customers for shipping and handling of products and tissues are included in product and preservation service revenues. The costs for shipping and handling of products and tissues are included as a component of cost of products and cost of preservation services. Taxes Collected from Customers Taxes collected on the value of transaction revenue are excluded from product and service revenues and cost of sales and are accrued in current liabilities until remitted to governmental authorities. Advertising Costs The costs to develop, produce, and communicate our advertising are expensed as incurred and are classified as General, administrative, and marketing expenses. The total amount of advertising expense included in our Consolidated Statements of Operations and Comprehensive Loss was $1.0 million, $1.1 million, and $1.7 million for the years ended December 31, 2021, 2020, and 2019, respectively. Stock-Based Compensation We have stock option and stock incentive plans for employees and non-employee directors that provide for grants of restricted stock awards (“RSA”s), restricted stock units (“RSU”s), performance stock units (“PSU”s), and options to purchase shares of our common stock at exercise prices generally equal to the fair values of such stock at the dates of grant. We also maintain a shareholder approved Employee Stock Purchase Plan (the “ESPP”) for the benefit of our employees. The ESPP allows eligible employees the right to purchase common stock on a regular basis at the lower of 85% of the market price at the beginning or end of each offering period. The RSAs, RSUs, PSUs, and stock options granted by us typically vest over a one to three-year period. The stock options granted by us typically expire within seven years of the grant date. We value our RSAs, RSUs, and PSUs based on the stock price on the date of grant. We expense the related compensation cost of RSAs, and RSUs using the straight-line method over the vesting period. We expense the related compensation cost of PSUs based on the number of shares expected to be issued, if achievement of the performance component is probable, using a straight-line method over each vesting tranche of the award which results in accelerated recognition of expenses. The amount of compensation costs expensed related to PSUs is adjusted as needed if we deem that achievement of the performance component is no longer probable or if our expectation of the number of shares to be issued changes. We use a Black-Scholes model to value our stock option grants and expense the related compensation cost using the straight-line method over the vesting period. The fair value of our ESPP options is also determined using a Black-Scholes model and is expensed over the vesting period. The fair value of stock options and ESPP options is determined on the grant date using assumptions for the expected term, volatility, dividend yield, and the risk-free interest rate. The expected term is primarily based on the contractual term of the option and our data related to historic exercise and post-vesting forfeiture patterns, which is adjusted based on our expectations of future results. Our anticipated volatility level is primarily based on the historic volatility of our common stock, adjusted to remove the effects of certain periods of unusual volatility not expected to recur, and adjusted based on our expectations of future volatility, for the life of the option or option group. Our model includes a zero-dividend yield assumption and we do not anticipate paying dividends in the future. The risk-free interest rate is based on recent US Treasury note auction results with a similar life to that of the option. Our model does not include a discount for post-vesting restrictions, as we have not issued awards with such restrictions. The period expense for our stock compensation is determined based on the valuations discussed above and forfeitures are accounted for in the period awards are forfeited. Income Per Common Share Income per common share is computed using the two-class method, which requires us to include unvested RSAs that contain non-forfeitable rights to dividends (whether paid or unpaid) as participating securities in the income per common share calculation. Under the two-class method, net income is allocated to the weighted-average number of common shares outstanding during the period and the weighted-average participating securities outstanding during the period. The portion of net income that is allocated to the participating securities is excluded from basic and dilutive net income per common share. Diluted net income per share is computed using the weighted-average number of common shares outstanding plus the dilutive effects of outstanding stock options and awards and other dilutive instruments as appropriate. Financial Instruments Our financial instruments include cash equivalents, restricted securities, accounts receivable, notes receivable, accounts payable, and debt obligations. The financial assets’ and liabilities’ such as receivables, and accounts payable carrying values approximate their fair value due to their short-term duration, and the carrying value of their debt obligations approximate fair value as they contain variable interest rates that approximate market values. Other financial instruments are recorded as discussed in the sections below. Fair Value Measurements We record certain financial instruments at fair value on a recurring basis, including cash equivalents and certain restricted securities. We may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis. Fair value financial instruments are recorded in accordance with the fair value measurement framework. We also measure certain assets and liabilities at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as certain financial assets, long-lived assets, and non-amortizing intangible assets for impairment, allocating value to assets in an acquired asset group, applying accounting for business combinations, and the initial recognition of liabilities such as contingent consideration. We use the fair value measurement framework to value these assets and labilities and report these fair values in the periods in which they are recorded or written down. The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; andLevel 3: Unobservable inputs or valuation techniques that are used when little or no market data is available. The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to our unobservable estimates and assumptions. Our assumptions could vary depending on the asset or liability value and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. We may also engage external advisors to assist in determining fair value, as appropriate. Although we believe that the recorded fair values of our financial instruments are appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values. Cash and Cash Equivalents Cash and cash equivalents consist primarily of highly liquid investments with maturity dates of three months or less at the time of acquisition. The carrying value of cash equivalents approximates fair value. We maintain depository accounts with certain financial institutions. Although these depository accounts may exceed government insured depository limits, we have evaluated the credit worthiness of these applicable financial institutions and determined the risk of material financial loss due to the exposure of such credit risk to be minimal. Cash Flow Supplemental Disclosures Supplemental disclosures of cash flow information for the years ended December 31 (in thousands): 2021 2020 2019Cash paid during the year for: Interest$ 14,407 $ 13,049 $ 13,297Income taxes 5,483 4,122 1,944 Non-cash investing and financing activities: Issuance of common stock for Ascyrus Acquisition$ -- $ 20,000 $ --Issuance of common stock for contingent consideration 10,000 -- --Operating lease right of use assets 31,726 1,864 2,604 Accounts Receivable and Allowance for Doubtful Accounts Our accounts receivable are primarily from hospitals and distributors that either use or distribute our products and tissues. We assess the likelihood of collection based on a number of factors, including past transaction history and the credit worthiness of the customer, as well as the potential increased risks related to international customers and large distributors. We determine the allowance for doubtful accounts based upon specific reserves for known collection issues, as well as a non-specific reserve based upon aging buckets. We charge off uncollectible amounts against the reserve in the period in which we determine they are uncollectible. Our accounts receivable balances are reported net of allowance for doubtful accounts of $1.1 million and $973,000 as of December 31, 2021 and 2020, respectively. Inventories, net Inventories, net are comprised of finished goods for our product lines including: aortic stents and stent grafts; surgical sealants; On-X products; CardioGenesis laser consoles, handpieces, and accessories; PerClot before the Baxter Transaction defined below; PhotoFix; other medical devices; work-in-process; and raw materials. Inventories for finished goods are valued at the lower of cost or market on a first-in, first-out basis and raw materials are valued on a moving average cost basis. Typically, upon shipment or upon implant of a medical device on consignment, revenue is recognized, and the related inventory costs are expensed as cost of products. Cost of products also includes, as applicable, lower of cost or market write-downs and impairments for products not deemed to be recoverable and, as incurred, idle facility expense, excessive spoilage, extra freight, and re-handling costs. Inventory costs for manufactured products consist primarily of direct labor and materials (including salary and fringe benefits, raw materials, and supplies) and indirect costs (including allocations of costs from departments that support manufacturing activities and facility allocations). The allocation of fixed production overhead costs is based on actual production levels, to the extent that they are within the range of the facility’s normal capacity. Inventory costs for products purchased for resale or manufactured under contract consist primarily of the purchase cost, freight-in charges, and indirect costs as appropriate. We regularly evaluate our inventory to determine if the costs are appropriately recorded at the lower of cost or market value. We also evaluate our inventory for costs not deemed to be recoverable, including inventory not expected to ship prior to its expiration. Lower of cost or market value write-downs are recorded if the book value exceeds the estimated net realizable value of the inventory, based on recent sales prices at the time of the evaluation. Impairment write-downs are recorded based on the book value of inventory deemed to be impaired. Actual results may differ from these estimates. Write-downs of inventory are expensed as cost of products, and these write-downs are permanent impairments that create a new cost basis, which cannot be restored to its previous levels if our estimates change. We recorded write-downs to our inventory totaling $4.8 million, $1.7 million, and $601,000 for the years ended December 31, 2021, 2020, and 2019, respectively. The 2021 write-down was primarily related to JOTEC inventory and On-X ascending aortic prosthesis (“AAP”) inventory. The 2020 write-down was primarily related to JOTEC inventory, On-X AAP inventory, and BioGlue inventory not expected to ship prior to the expiration date. The 2019 write-down was primarily related to PerClot inventory not expected to ship prior to the expiration date. Deferred Preservation Costs Deferred preservation costs include costs of cardiac and vascular tissues available for shipment, tissues currently in active processing, and tissues held in quarantine pending release to implantable status. By federal law, human tissues cannot be bought or sold; therefore, the tissues we preserve are not held as inventory. The costs we incur to procure and process cardiac and vascular tissues are instead accumulated and deferred. Deferred preservation costs are stated at the lower of cost or market value on a first-in, first-out basis and are deferred until revenue is recognized. Upon shipment of tissue to an implanting facility, revenue is recognized, and the related deferred preservation costs are expensed as cost of preservation services. Cost of preservation services also includes, as applicable, lower of cost or market write-downs and impairments for tissues not deemed to be recoverable, and includes, as incurred, idle facility expense, excessive spoilage, extra freight, and re-handling costs. The calculation of deferred preservation costs involves judgment and complexity and uses the same principles as inventory costing. Donated human tissue is procured from deceased human donors by organ and tissue procurement organizations (“OPOs”) and tissue banks, that provide the tissue to us for processing, preservation, and distribution. Deferred preservation costs consist primarily of the procurement fees charged by the OPOs and tissue banks, direct labor and materials (including salary and fringe benefits, laboratory supplies and expenses, and freight-in charges), and indirect costs (including allocations of costs from support departments and facility allocations). Fixed production overhead costs are allocated based on actual tissue processing levels, to the extent that they are within the range of the facility’s normal capacity. These costs are then allocated among the tissues processed during the period based on cost drivers, such as the number of donors or number of tissues processed. We apply a yield estimate to all tissues in process and in quarantine to estimate the portion of tissues that will ultimately become implantable. We estimate quarantine and in process yields based on our experience and reevaluate these estimates periodically. Actual yields could differ significantly from our estimates, which could result in a change in tissues available for shipment and could increase or decrease the balance of deferred preservation costs. These changes could result in additional cost of preservation services expense or could increase per tissue preservation costs, which would impact gross margins on tissue preservation services in future periods. We regularly evaluate our deferred preservation costs to determine if the costs are appropriately recorded at the lower of cost or market value. We also evaluate our deferred preservation costs for costs not deemed to be recoverable, including tissues not expected to ship prior to the expiration date of their packaging. Lower of cost or market value write-downs are recorded if the tissue processing costs incurred exceed the estimated market value of the tissue services, based on recent average service fees at the time of the evaluation. Impairment write-downs are recorded based on the book value of tissues deemed to be impaired. Actual results may differ from these estimates. Write-downs of deferred preservation costs are expensed as cost of preservation services, and these write-downs are permanent impairments that create a new cost basis, which cannot be restored to its previous levels if our estimates change. We recorded write-downs to our deferred preservation costs totaling $575,000, $1.7 million, and $787,000 for the years ended December 31, 2021, 2020, and 2019, respectively, due primarily to tissues not expected to ship prior to the expiration date of the packaging. In addition, write-offs during the year ended December 31, 2020 included $826,000 of non-conforming tissues resulting from contaminated saline solution. Property and Equipment, net Property and equipment, net is stated at cost less depreciation. Depreciation expense is recorded over the estimated useful lives of the assets, generally three to ten years, on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the remaining lease term at the time the assets are capitalized or the estimated useful lives of the assets, whichever is shorter. Property and equipment, net balance for the years ended December 31 is as follows (in thousands): 2021 2020Equipment and software$ 73,820 $ 66,141Furniture and fixtures 6,668 6,186Leasehold improvements 39,175 38,256Total property and equipment 119,663 110,583Less accumulated depreciation and amortization 82,142 77,506Property and equipment, net $ 37,521 $ 33,077 Depreciation expense for the years ended December 31 is as follows (in thousands): 2021 2020 2019Depreciation expense$ 7,157 $ 6,948 $ 7,467 Goodwill and Other Intangible Assets Our intangible assets consist of goodwill, acquired technology, customer lists and relationships, patents, trademarks, and other intangible assets, as discussed in Note 8. Our goodwill is attributable to a segment or segments of our business, as appropriate, as the related acquired business that generated the goodwill is integrated into our operations. Upon divestiture of a component of our business, the goodwill related to the reporting unit is allocated to the divested business using the relative fair value allocation method. We evaluate our goodwill and other non-amortizing intangible assets for impairment on an annual basis during the fourth quarter of the year, and, if necessary, during interim periods if factors indicate that an impairment review is warranted. As of October 31, 2021 and 2020, our non-amortizing intangible assets consisted of goodwill, in-process research and development, acquired procurement contracts and agreements, and trademarks. We performed a qualitative analysis of our non-amortizing intangible assets as of October 31, 2021 and 2020 and determined that the fair value of the assets and the fair value of the reporting unit more likely than not exceeded their associated carrying values and were, therefore, not impaired. Our definite lived intangible assets consist of acquired technologies, customer lists and relationships, distribution and manufacturing rights and know-how, patents, and other intangible assets. We amortize our definite lived intangible assets over their expected useful lives using the straight-line method, which we believe approximates the period of economic benefits of the related assets. Our indefinite lived intangible assets do not amortize but are instead subject to periodic impairment testing as discussed in “Impairments of Long-Lived Assets and Non-Amortizing Intangible Assets” below. Impairments of Long-Lived Assets and Non-Amortizing Intangible Assets Long-Lived Assets We assess the potential impairment of our: (i) net property and equipment, (ii) amortizing intangible long-lived assets to be held and used and (iii) operating lease right-of-use assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors that could trigger an impairment review include, but are not limited to, the following: Significant underperformance relative to expected historical or projected future operating results; Significant negative industry or economic trends; Significant decline in our stock price for a sustained period; orSignificant decline in our market capitalization relative to net book value. If we determine that an impairment review is necessary, we will evaluate the assets or asset groups by comparing their carrying values to the sum of the undiscounted future cash flows expected to result from their use and eventual disposition. If the carrying values exceed the future cash flows, then the asset or asset group is considered impaired, and we will write down the value of the asset or asset group to its concluded fair value. For the years ended December 31, 2021, 2020, and 2019 we did not record an impairment of our long-lived assets as there were no indicators of impairment or the sum of the undiscounted future cash flows exceeded the carrying value of the long-lived asset (asset group). Accrued Procurement Fees Donated tissue is procured from deceased human donors by OPOs and tissue banks, that provide the tissue to us for processing, preservation, and distribution. We reimburse the OPOs and tissue banks for their costs to recover the tissue and include these costs as part of deferred preservation costs, as discussed above. We accrue estimated procurement fees due to the OPOs and tissue banks at the time tissues are received based on contractual agreements between us and the OPOs and tissue banks. Leases We have operating and finance lease obligations resulting from the lease of land and buildings that comprise our corporate headquarters and various manufacturing facilities; leases related to additional manufacturing, office, and warehouse space; leases on Company vehicles; and leases on a variety of office and other equipment, as discussed in Note 10. Certain of our leases contain escalation clauses, rent concessions, and renewal options for additional periods. We exercise judgment in the determination of whether a financial arrangement includes a lease and in determining the appropriate discount rates to be applied to leases based on our general collateralized credit standing and the geographical market considerations impacting lease rates across all locations. When available, we use the implicit discount rate in the lease contract to discount lease payments to present value. If an implicit discount rate is not available in the lease contract, we use our incremental borrowing rate. We elected the package of practical expedients that allow us to omit leases with initial terms of 12 months or less from our balance sheet, which are expensed on a straight-line basis over the life of the lease. We have elected not to separate lease and non-lease components for future leases. Our leases do not include terms or conditions which would result in variable lease payments other than for small office equipment leases with an additional charge for volume of usage. These incremental payments are excluded from our calculation of lease liability and the related right-of-use asset. We do not include option terms in the determination of lease liabilities and the related right-of-use assets unless we determine at lease commencement that the exercise of the option is reasonably certain. Our leases do not contain residual value guarantee provisions or other restrictions or financial covenant provisions. Debt Issuance Costs Debt issuance costs related to our term loan and line of credit are capitalized and reported net of the current and long-term debt or as a prepaid asset when there are no outstanding borrowings. If there are unamortized debt issuance costs related to our line of credit but only borrowings on the term loan, these debt issuance costs will be combined with the debt issuance costs related to the term loan and reported net of the current and long-term debt for the term loan. We amortize debt issuance costs to interest expense on our term loan using the effective interest method over the life of the debt agreement. We amortize debt issuance costs to interest expense on our line of credit on a straight-line basis over the life of the debt agreement. Debt issuance costs related to our convertible debt agreement are amortized using the effective interest rate method as a direct deduction from the recorded debt issuance costs allocated to debt. Liability Claims In the normal course of business, we are made aware of adverse events involving our products and tissues. Future adverse events could ultimately give rise to a lawsuit against us, and liability claims may be asserted against us in the future based on past events that we are not aware of at the present time. We maintain claims-made insurance policies to mitigate our financial exposure to product and tissue processing liability claims. Claims-made insurance policies generally cover only those asserted claims and incidents that are reported to the insurance carrier while the policy is in effect. Thus, a claims-made policy does not generally represent a transfer of risk for claims and incidents that have been incurred but not reported to the insurance carrier during the policy period. Any punitive damage components of claims are uninsured. We engage external advisors to assist us in estimating our liability and any related amount recoverable under our insurance policies as of each balance sheet date. We use a frequency-severity approach to estimate our unreported product and tissue processing liability claims, whereby projected losses are calculated by multiplying the estimated number of claims by the estimated average cost per claim. The estimated claims are determined based on the reported claim development method and the Bornhuetter-Ferguson method using a blend of our historical claim experience and industry data. The estimated cost per claim is calculated using a lognormal claims model blending our historical average cost per claim with industry claims data. We use a number of assumptions in order to estimate the unreported loss liability including: the future claim reporting time lag, the frequency of reported claims, the average cost per claim, and the maximum liability per claim. We believe that the assumptions we use provide a reasonable basis for our calculation. However, the accuracy of the estimates is limited by various factors, including, but not limited to, our specific conditions, uncertainties surrounding the assumptions used, and the scarcity of industry data directly relevant to our business activities. Due to these factors, actual results may differ significantly from our assumptions and from the amounts accrued. We accrue our estimate of unreported product and tissue processing liability claims as a component of Other long-term liabilities and record the related recoverable insurance amounts as a component of Other long-term assets. The amounts recorded represent our estimate of the probable losses and anticipated recoveries for unreported claims related to products sold and services performed prior to the balance sheet date. Legal Contingencies We accrue losses from a legal contingency when the loss is both probable and reasonably estimable. The accuracy of our estimates of losses for legal contingencies is limited by uncertainties surrounding litigation. Therefore, actual results may differ significantly from the amounts accrued, if any. We accrue for legal contingencies as a component of accrued expenses and/or other long-term liabilities on our Consolidated Balance Sheets. Gains from legal contingencies are recorded when the contingency is resolved. Uncertain Tax Positions We periodically assess our uncertain tax positions and recognize tax benefits if they are “more-likely-than-not” to be upheld upon review by the appropriate taxing authority. We measure the tax benefit by determining the maximum amount that has a “greater than 50 percent likelihood” of ultimately being realized. We reverse previously accrued liabilities for uncertain tax positions when audits are concluded, statutes expire, administrative practices dictate that a liability is no longer warranted, or in other circumstances, as deemed necessary. These assessments can be complex, and we often obtain assistance from external advisors to make these assessments. We recognize interest and penalties related to uncertain tax positions in interest expense, net on our Consolidated Statements of Operations and Comprehensive Loss. See Note 9 for further discussion of our liabilities for uncertain tax positions. Deferred Income Taxes Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and tax return purposes. We assess the recoverability of our deferred tax assets and provide a valuation allowance against our deferred tax assets when, as a result of this analysis, we believe it is more likely than not that some portion or all of our deferred tax assets will not be realized. Assessing the recoverability of deferred tax assets involves judgment and complexity including the consideration of prudent and feasible tax planning. Estimates and judgments used in the determination of the need for a valuation allowance and in calculating the amount of a needed valuation allowance include, but are not limited to, the following: The ability to carry back deferred tax asset attributes to a prior tax year;Timing of the anticipated reversal of book/tax temporary differences; Projected future operating results; Anticipated future state tax apportionment; Timing and amounts of anticipated future taxable income; Evaluation of statutory limits regarding usage of certain tax assets; and Evaluation of the statutory periods over which certain tax assets can be utilized. Significant changes in the factors above, or other factors, could affect our ability to use our deferred tax assets. Such changes could have a material, adverse impact on our profitability, financial position, and cash flows. We will continue to assess the recoverability of our deferred tax assets, as necessary, when we experience changes that could materially affect our prior determination of the recoverability of our deferred tax assets. Valuation of Acquired Assets or Businesses As part of our corporate strategy, we are seeking to identify and capitalize upon acquisition opportunities of complementary product lines and companies. We evaluate and account for acquired patents, licenses, distribution rights, and other tangible or intangible assets as the purchase of an asset or asset group, or as a business combination, as appropriate. The determination of whether the purchase of a group of assets should be accounted for as an asset group or as a business combination requires judgment based on the weight of available evidence. For the purchase of an asset group, we allocate the cost of the asset group, including transaction costs, to the individual assets purchased based on their relative estimated fair values. In-process research and development acquired as part of an asset group is expensed upon acquisition. We account for business combinations using the acquisition method. Under this method, the allocation of the purchase price is based on the fair value of the tangible and identifiable intangible assets acquired and the liabilities assumed as of the date of the acquisition. The excess of the purchase price over the estimated fair value of the tangible net assets and identifiable intangible assets is recorded as goodwill. The identifiable intangible assets typically consist of developed technology, trade names, customer relationships, and in-process research and development costs. Transaction costs related to business combinations are expensed as incurred. In-process research and development acquired as part of a business combination is accounted for as an indefinite-lived intangible asset until the related research and development project gains regulatory approval or is discontinued. We typically engage external advisors to assist us in determining the fair value of acquired asset groups or business combinations, using valuation methodologies such as: the excess earnings, the discounted cash flow, Monte Carlo, or the relief from royalty methods. The determination of fair value in accordance with the fair value measurement framework requires significant judgments and estimates, including, but not limited to: timing of product life cycles, estimates of future revenues, estimates of profitability for new or acquired products, cost estimates for new or changed manufacturing processes, estimates of the cost or timing of obtaining regulatory approvals, estimates of the success of competitive products, and discount rates and represent Level 3 measurements. We, in consultation with our advisors, make these estimates based on our prior experiences and industry knowledge. We believe that our estimates are reasonable, but actual results could differ significantly from our estimates. A significant change in our estimates used to value acquired asset groups or business combinations could result in future write-downs of tangible or intangible assets acquired by us and, therefore, could materially impact our financial position and profitability. If the value of the liabilities assumed by us, including contingent liabilities, is determined to be significantly different from the amounts previously recorded in purchase accounting, we may need to record additional expenses or write-downs in future periods, which could materially impact our financial position and profitability. New Accounting Pronouncements Recently Adopted In August 2020 the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) Update No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”). The update simplifies the accounting for convertible instruments by eliminating two accounting models (i.e., the cash conversion model and beneficial conversion feature model) and reducing the number of embedded conversion features that could be recognized separately from the host contract. ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. On January 1, 2021 we adopted ASU 2020-06 using the modified retrospective approach and recorded $20.4 million to increase long-term debt, $3.2 million to reduce retained earnings, and $16.4 million to reduce additional paid-in capital included on the Consolidated Balance Sheets. See Note 11 for further discussion of convertible debt. In December 2019 the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify accounting principles generally accepted in the United States of America (“GAAP”) for other areas of Topic 740 by clarifying and amending existing guidance. The amendments are effective for public entities in fiscal years beginning after December 15, 2020 including interim periods within those fiscal years. We adopted ASU 2019-12 on January 1, 2021 and the adoption did not have a material impact on our financial condition or results of operations. As of January 1, 2020 we adopted the Accounting Standards Codification (“ASC”) No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019. The adoption of ASU 2016-13 did not result in a material effect on the Company’s financial condition, results of operations, or cash flows. As of January 1, 2019 we adopted the ASC Topic 842, Leases (“ASC 842”). The final guidance requires lessees to recognize a right-of-use asset and a lease liability for all leases (with the exception of short-term leases) at the commencement date and recognize expenses on their income statements similar to former Topic 840, Leases. We used the modified retrospective approach, which allows application of the standard at the adoption date rather than at the beginning of the earliest comparative period presented. The adoption of this standard resulted in the recognition of operating lease agreements with a net present value of $22.7 million and corresponding right-of-use assets obtained in the same amount at January 1, 2019. See Note 9 for further discussion of leases. Not Yet Effective In March 2020 the FASB issued ASU 2020-04, Reference Rate Reform Topic 848 (“ASC 848”). The amendments in this ASU were put forth in response to the market transition from the LIBOR and other interbank offered rates to alternative reference rates. GAAP requires entities to evaluate whether a contract modification, such as the replacement or change of a reference rate, results in the establishment of a new contract or continuation of an existing contract. ASC 848 allows an entity to elect not to apply certain modification accounting requirements to contracts affected by reference rate reform. The standard provides this temporary election through December 31, 2022 and cannot be applied to contract modifications that occur after December 31, 2022. In January 2021 the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848). The objective of the new reference rate reform standard is to clarify the scope of Topic 848 and provide explicit guidance to help companies applying optional expedients and exceptions. This ASU is effective immediately for all entities that have applied optional expedients and exceptions. We are in the process of evaluating the effect that the adoption of this standard will have on our financial position and results of operations.
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stents and stent grafts, surgical sealants, On-X® mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stents and stent grafts include JOTEC® stent grafts and surgical products (collectively, “JOTEC Products”), the Ascyrus Medical Dissection Stent (“AMDS”) hybrid prosthesis, and the NEXUS® endovascular stent graft system (“NEXUS”). Surgical sealants include BioGlue® Surgical Adhesive (“BioGlue”) products. In addition to these four major product families, we sell or distribute PhotoFix® bovine surgical patches, CardioGenesis® cardiac laser therapy, Therion® chorioamniotic allografts (previously marketed as NeoPatch®), and PerClot® hemostatic powder (prior to the sale to a subsidiary of Baxter International, Inc (“Baxter”)).
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5500000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1800000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1200000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with US GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Estimates and assumptions are used when accounting for allowance for doubtful accounts, inventory, deferred preservation costs, acquired assets or businesses, intangible assets, deferred income taxes, commitments and contingencies (including product and tissue processing liability claims, claims incurred but not reported, and amounts recoverable from insurance companies), stock based compensation, certain accrued liabilities (including accrued procurement fees, income taxes, and financial instruments), and other items as appropriate.
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1000000.0
CY2020	us-gaap	Advertising Expense AdvertisingExpense	1100000
CY2019	us-gaap	Advertising Expense AdvertisingExpense	1700000
CY2021	us-gaap	Interest Paid InterestPaid	14407000
CY2020	us-gaap	Interest Paid InterestPaid	13049000
CY2019	us-gaap	Interest Paid InterestPaid	13297000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	5483000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	4122000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	1944000
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	20000000
CY2021	aort	Noncash Or Part Noncash Acquisition Stock Issued For Contingent Consideration NoncashOrPartNoncashAcquisitionStockIssuedForContingentConsideration	10000000
CY2021	aort	Noncash Or Part Noncash Acquisition Assets Acquired In Exchange For Operating Leases NoncashOrPartNoncashAcquisitionAssetsAcquiredInExchangeForOperatingLeases	31726000
CY2020	aort	Noncash Or Part Noncash Acquisition Assets Acquired In Exchange For Operating Leases NoncashOrPartNoncashAcquisitionAssetsAcquiredInExchangeForOperatingLeases	1864000
CY2019	aort	Noncash Or Part Noncash Acquisition Assets Acquired In Exchange For Operating Leases NoncashOrPartNoncashAcquisitionAssetsAcquiredInExchangeForOperatingLeases	2604000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1100000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	973000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	4800000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	1700000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	601000
CY2021	aort	Deferred Preservation Costs Write Down DeferredPreservationCostsWriteDown	575000
CY2020	aort	Deferred Preservation Costs Write Down DeferredPreservationCostsWriteDown	1700000
CY2019	aort	Deferred Preservation Costs Write Down DeferredPreservationCostsWriteDown	787000
CY2020	aort	Non Conforming Tissues Write Down NonConformingTissuesWriteDown	826000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	119663000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	110583000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	82142000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	77506000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37521000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33077000
CY2021	us-gaap	Depreciation Depreciation	7157000
CY2020	us-gaap	Depreciation Depreciation	6948000
CY2019	us-gaap	Depreciation Depreciation	7467000
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	aort	Securites Purchase Option Agreement Expiration Period SecuritesPurchaseOptionAgreementExpirationPeriod	P90D
CY2021	aort	Number Of Tranches NumberOfTranches	3
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	10015000
CY2021Q4	aort	Contingent Consideration Noncurrent Fair Value ContingentConsiderationNoncurrentFairValue	49400000
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	49400000
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	12439000
CY2020Q4	aort	Contingent Consideration Current Fair Value ContingentConsiderationCurrentFairValue	16430000
CY2020Q4	aort	Contingent Consideration Noncurrent Fair Value ContingentConsiderationNoncurrentFairValue	43500000
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	59930000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	10015000
CY2021Q4	aort	Restricted Cash Fair Value Disclosure RestrictedCashFairValueDisclosure	10015000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	12030000
CY2020Q4	aort	Restricted Cash Fair Value Disclosure RestrictedCashFairValueDisclosure	12030000
CY2019	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0
CY2020	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	35780000
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	33625000
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9712000
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6318000
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	31479000
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	33095000
CY2021Q4	us-gaap	Inventory Net InventoryNet	76971000
CY2020Q4	us-gaap	Inventory Net InventoryNet	73038000
CY2021Q4	aort	Deferred Preservation Costs DeferredPreservationCosts	42863000
CY2020Q4	aort	Deferred Preservation Costs DeferredPreservationCosts	36546000
CY2021Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	12900000
CY2020Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	11900000
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3200000
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3500000
CY2021Q4	us-gaap	Goodwill Goodwill	250000000
CY2020Q4	us-gaap	Goodwill Goodwill	260061000
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2020Q4	us-gaap	Goodwill Goodwill	260061000
CY2019Q4	us-gaap	Goodwill Goodwill	186697000
CY2021	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-942000
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	63357000
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-9119000
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	10007000
CY2021Q4	us-gaap	Goodwill Goodwill	250000000
CY2020Q4	us-gaap	Goodwill Goodwill	260061000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16820000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13764000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10850000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	15765000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	15261000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	14885000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	12878000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	12650000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17174000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	707000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2041000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5838000
CY2021Q4	aort	Finite Lived Intangible Assets Amortization Expense Estimate FiniteLivedIntangibleAssetsAmortizationExpenseEstimate	71439000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-10263000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-11443000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	6369000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4564000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5731000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4725000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14827000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1644000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1896000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-2460000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	48000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	551000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	445000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	80000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3391000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-1308000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2169000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2801000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1721000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-850000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-307000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	384000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-131000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2723000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1289000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1264000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5831000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	816000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2245000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-492000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-76000
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	425000
CY2021	aort	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Cost Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationCostAmount	1075000
CY2020	aort	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Cost Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationCostAmount	580000
CY2019	aort	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Cost Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationCostAmount	778000
CY2021	aort	Effective Income Tax Rate Reconciliation Net Change In Uncertain Tax Positions Amount EffectiveIncomeTaxRateReconciliationNetChangeInUncertainTaxPositionsAmount	762000
CY2020	aort	Effective Income Tax Rate Reconciliation Net Change In Uncertain Tax Positions Amount EffectiveIncomeTaxRateReconciliationNetChangeInUncertainTaxPositionsAmount	-1115000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.03
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.05
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	aort	Effective Income Tax Rate Reconciliation Net Change In Uncertain Tax Positions Amount EffectiveIncomeTaxRateReconciliationNetChangeInUncertainTaxPositionsAmount	-360000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1138000
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	378000
CY2021	aort	Effective Income Tax Rate Reconciliation Foreign Interest Disallowance Amount EffectiveIncomeTaxRateReconciliationForeignInterestDisallowanceAmount	307000
CY2020	aort	Effective Income Tax Rate Reconciliation Foreign Interest Disallowance Amount EffectiveIncomeTaxRateReconciliationForeignInterestDisallowanceAmount	298000
CY2019	aort	Effective Income Tax Rate Reconciliation Foreign Interest Disallowance Amount EffectiveIncomeTaxRateReconciliationForeignInterestDisallowanceAmount	292000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	73000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-455000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-108000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	65000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3114000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3606000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	345000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1566000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3952000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	153000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	94000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	201000
CY2021	aort	Effective Income Tax Rate Reconciliation Foreign Deferred Items Amount EffectiveIncomeTaxRateReconciliationForeignDeferredItemsAmount	53000
CY2020	aort	Effective Income Tax Rate Reconciliation Foreign Deferred Items Amount EffectiveIncomeTaxRateReconciliationForeignDeferredItemsAmount	-63000
CY2019	aort	Effective Income Tax Rate Reconciliation Foreign Deferred Items Amount EffectiveIncomeTaxRateReconciliationForeignDeferredItemsAmount	365000
CY2021	aort	Income Tax Rate Reconciliation Deductible Equity Compensation IncomeTaxRateReconciliationDeductibleEquityCompensation	477000
CY2020	aort	Income Tax Rate Reconciliation Deductible Equity Compensation IncomeTaxRateReconciliationDeductibleEquityCompensation	204000
CY2019	aort	Income Tax Rate Reconciliation Deductible Equity Compensation IncomeTaxRateReconciliationDeductibleEquityCompensation	1921000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	959000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	457000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	400000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-482000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	106000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	154000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-492000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-76000
CY2021Q4	aort	Deferred Tax Asseets Finance And Operating Leases DeferredTaxAsseetsFinanceAndOperatingLeases	13762000
CY2020Q4	aort	Deferred Tax Asseets Finance And Operating Leases DeferredTaxAsseetsFinanceAndOperatingLeases	6880000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6649000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7911000
CY2021Q4	aort	Deferred Tax Assets Excess Interest Carryforwards DeferredTaxAssetsExcessInterestCarryforwards	3547000
CY2020Q4	aort	Deferred Tax Assets Excess Interest Carryforwards DeferredTaxAssetsExcessInterestCarryforwards	2660000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2088000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2002000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2007000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2034000
CY2021Q4	aort	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Deferred Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsDeferredCompensation	1535000
CY2020Q4	aort	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Deferred Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsDeferredCompensation	1326000
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1356000
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1397000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	601000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1214000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	397000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	308000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3770000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2798000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13282000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7170000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	22430000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	21360000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	29086000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	35770000
CY2021Q4	aort	Deferred Tax Liabilities Finance And Operating Leases DeferredTaxLiabilitiesFinanceAndOperatingLeases	13404000
CY2020Q4	aort	Deferred Tax Liabilities Finance And Operating Leases DeferredTaxLiabilitiesFinanceAndOperatingLeases	6617000
CY2021Q4	aort	Deferred Tax Liabilities Unrealized Gains And Losses DeferredTaxLiabilitiesUnrealizedGainsAndLosses	4088000
CY2020Q4	aort	Deferred Tax Liabilities Unrealized Gains And Losses DeferredTaxLiabilitiesUnrealizedGainsAndLosses	4929000
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	1024000
CY2020Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	1528000
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	395000
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	417000
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts	105000
CY2020Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	4700000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	770000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	665000
CY2021Q4	aort	Deferred Tax Assets Excess Interest Carryforwards DeferredTaxAssetsExcessInterestCarryforwards	3500000
CY2021	aort	Interest Deductibility Rule Interest Deduction Limit Tax Cuts And Jobs Act And Cares Act InterestDeductibilityRuleInterestDeductionLimitTaxCutsAndJobsActAndCaresAct	11700000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	3000000.0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1800000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	500000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	110000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	48872000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	54626000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	26442000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	33266000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	26400000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	33300000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13300000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7200000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	2000000.0
CY2020	aort	Interest Deductibility Rule Interest Deduction Limit Tax Cuts And Jobs Act And Cares Act InterestDeductibilityRuleInterestDeductionLimitTaxCutsAndJobsActAndCaresAct	15800000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2574000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3523000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3889000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1661000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	473000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	691000
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	241000
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1703000
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	880000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	170000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	238000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	154000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Foreign Currency Translation UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation	121000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Foreign Currency Translation UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation	99000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Foreign Currency Translation UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation	22000
CY2021	aort	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	386000
CY2020	aort	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	420000
CY2019	aort	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-1000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4089000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2574000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3523000
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	220000
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	261000
CY2021Q4	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	35000
CY2020Q4	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	180000
CY2019Q4	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	-27000
CY2021Q4	aort	Liability For Uncertain Tax Positions LiabilityForUncertainTaxPositions	4300000
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	300000
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	4000000.0
CY2021Q4	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	3200000
CY2020Q4	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	2600000
CY2019Q4	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	3500000
CY2020Q4	aort	Liability For Uncertain Tax Positions LiabilityForUncertainTaxPositions	2800000
CY2020Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	300000
CY2020Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2500000
CY2021	us-gaap	Income Tax Examination Estimate Of Possible Loss IncomeTaxExaminationEstimateOfPossibleLoss	185000
CY2021Q4	aort	Operating Lease Right Of Use Assets At Cost OperatingLeaseRightOfUseAssetsAtCost	58097000
CY2020Q4	aort	Operating Lease Right Of Use Assets At Cost OperatingLeaseRightOfUseAssetsAtCost	28242000
CY2021Q4	aort	Operating Lease Right Of Use Assets Accumulated Amortization OperatingLeaseRightOfUseAssetsAccumulatedAmortization	12383000
CY2020Q4	aort	Operating Lease Right Of Use Assets Accumulated Amortization OperatingLeaseRightOfUseAssetsAccumulatedAmortization	9671000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45714000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18571000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3149000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5763000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44869000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14034000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	48018000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	19797000
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	6759000
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	7620000
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	2105000
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	1905000
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	4654000
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	5715000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	528000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	614000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4374000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	5300000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	4902000
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	5914000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y6M
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P8Y9M18D
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.020
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P9Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.020
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5188000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	579000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6174000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	599000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	596000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	643000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	110000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	118000
CY2021	aort	Finance Lease Cost FinanceLeaseCost	706000
CY2020	aort	Finance Lease Cost FinanceLeaseCost	761000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7521000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	7145000
CY2021	us-gaap	Sublease Income SubleaseIncome	399000
CY2020	us-gaap	Sublease Income SubleaseIncome	905000
CY2021	us-gaap	Lease Cost LeaseCost	7828000
CY2020	us-gaap	Lease Cost LeaseCost	7001000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	6600000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6061000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	7407000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	557000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	653000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	105000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	126000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	600000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5928000
CY2021Q4	aort	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Next Twelve Months OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInNextTwelveMonths	306000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	629000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5619000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	623000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4797000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	2318000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	42210000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	5348000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	69916000
CY2021Q4	us-gaap	Property Subject To Or Available For Operating Lease Net PropertySubjectToOrAvailableForOperatingLeaseNet	306000
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	446000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	21898000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	48018000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	528000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	4902000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3149000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4374000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44869000
CY2021Q4	aort	Debt Instrument Debt Default Interest Rate DebtInstrumentDebtDefaultInterestRate	0.0200
CY2021	us-gaap	Line Of Credit Facility Commitment Fee Percentage LineOfCreditFacilityCommitmentFeePercentage	0.0050
CY2021Q4	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.0450
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	317627000
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	300148000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8504000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8485000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	309123000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	291663000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1630000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1195000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	307493000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	290468000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2785000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2785000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2596000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	102462000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	2250000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	204749000
CY2021Q4	aort	Long Term Debt Including Convertible Debt LongTermDebtIncludingConvertibleDebt	317627000
CY2021	us-gaap	Interest Expense InterestExpense	16900000
CY2020	us-gaap	Interest Expense InterestExpense	16700000
CY2019	us-gaap	Interest Expense InterestExpense	14900000
CY2020Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	5500000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	13575000
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.035
CY2021Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	6600000
CY2020Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	6400000
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	378000
CY2020Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	68000
CY2021Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	6000000.0
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298836000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	253227000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	276222000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3373000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4296000
CY2021	aort	Number Of Performance Stock Unit Grants NumberOfPerformanceStockUnitGrants	2
CY2020	aort	Percentage Of Target Number Of Shares Of Common Stock Granted As Performance Stock Units PercentageOfTargetNumberOfSharesOfCommonStockGrantedAsPerformanceStockUnits	0.83
CY2021	us-gaap	Pension Expense Reversal Of Expense Noncash PensionExpenseReversalOfExpenseNoncash	1900000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	7300000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	6700000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	9800000
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	87000
CY2020	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	83000
CY2019	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	61000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	11277000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	7504000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	9411000
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	566000
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	592000
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	612000
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14834000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16682000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	1720000
CY2021	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-94000
CY2020	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-111000
CY2019	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	12000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14740000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16571000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1708000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38983000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37861000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37118000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14834000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16682000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	1720000
CY2021	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-94000
CY2020	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-111000
CY2019	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	12000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14740000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16571000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1708000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38983000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37861000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37118000
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	742000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38983000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37861000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37860000
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2021	us-gaap	Revenues Revenues	298836000
CY2020	us-gaap	Revenues Revenues	253227000
CY2019	us-gaap	Revenues Revenues	276222000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	101322000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	85443000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	93209000
CY2021	us-gaap	Gross Profit GrossProfit	197514000
CY2020	us-gaap	Gross Profit GrossProfit	167784000
CY2019	us-gaap	Gross Profit GrossProfit	183013000
CY2021	us-gaap	Revenues Revenues	298836000
CY2020	us-gaap	Revenues Revenues	253227000
CY2019	us-gaap	Revenues Revenues	276222000
CY2021	us-gaap	Revenues Revenues	298836000
CY2020	us-gaap	Revenues Revenues	253227000
CY2019	us-gaap	Revenues Revenues	276222000

Files In Submission

Name	View Source	Status
0000784199-22-000076-index-headers.html	Edgar Link	pending
0000784199-22-000076-index.html	Edgar Link	pending
0000784199-22-000076.txt	Edgar Link	pending
0000784199-22-000076-xbrl.zip	Edgar Link	pending
aort-20211231.xsd	Edgar Link	pending
aort-20211231x10k.htm	Edgar Link	pending
aort-20211231x10k_htm.xml	Edgar Link	completed
aort-20211231xex10_6.htm	Edgar Link	pending
aort-20211231xex21_1.htm	Edgar Link	pending
aort-20211231xex23_1.htm	Edgar Link	pending
aort-20211231xex31_1.htm	Edgar Link	pending
aort-20211231xex31_2.htm	Edgar Link	pending
aort-20211231xex32.htm	Edgar Link	pending
aort-20211231_cal.xml	Edgar Link	unprocessable
aort-20211231_def.xml	Edgar Link	unprocessable
aort-20211231_lab.xml	Edgar Link	unprocessable
aort-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AORT
ARTIVION, INC. Stock $aort

2021 Q4 Form 10-K Financial Statement

#000078419922000076 Filed on February 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AORT ARTIVION, INC. Stock $aort

2021 Q4 Form 10-K Financial Statement

#000078419922000076 Filed on February 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AORT
ARTIVION, INC. Stock $aort